Table 3. Baseline EORTC scores in the lenalidomide cohort and bortezomib dosage cohorts, presented as mean (s.d.).
| EORTC questionnaire | Domain | Bortezomib (N=96) | Lenalidomide (N=162) |
|---|---|---|---|
| QLQ-C30 | Global health status/QoL | 54.6 (25.7) | 54.8 (23.8) |
| Physical functioning | 69.1 (27.1) | 63.7 (27.0) | |
| Role functioning | 58.9 (34.5) | 56.7 (36.9) | |
| Emotional functioning | 69.6 (25.7) | 70.3 (23.8) | |
| Cognitive functioning | 79.5 (21.1) | 77.1 (25.6) | |
| Social functioning | 69.8 (31.7) | 68.6 (32.6) | |
| Fatigue | 42.6 (28.1) | 43.0 (28.7) | |
| Nausea and vomiting | 6.7 (15.0) | 8.5 (18.9) | |
| Pain | 36.1 (34.1) | 39.7 (33.8) | |
| Dyspnoea | 21.5 (26.6) | 26.9 (28.6) | |
| Insomnia | 32.6 (33.3) | 27.2 (32.2) | |
| Appetite loss | 19.9 (28.4) | 21.4 (31.2) | |
| Constipation | 19.1 (26.4) | 26.5 (33.5) | |
| Diarrhoea | 7.3 (16.3) | 9.7 (21.1) | |
| Financial difficulties | 15.6 (26.8) | 13.6 (24.2) | |
| QLQ-MY20 | Body image | 79.1 (30.9) | 79.5 (30.1) |
| Future perspective | 54.3 (28.0) | 52.7 (30.0) | |
| Disease symptoms | 26.0 (22.5) | 27.9 (22.8) | |
| Side effects of treatment | 18.1 (13.5) | 20.8 (15.3) | |
| QLQ-CIPN20 | Autonomic scale | 11.1 (15.5) | 14.0 (20.0) |
| Motor scale | 11.9 (13.5) | 17.9 (17.6) | |
| Sensory scale | 12.3 (15.1) | 16.7 (19.2) |
Abbreviations: EORTC; European Organization for Research and Treatment of Cancer; QLQ-C30, Quality-of-Life Core; QLQ-CIPN20, QLQ-Chemotherapy-Induced Peripheral Neuropathy; QLQ-MY20, QLQ-Multiple Myeloma; QoL, quality of life.